Statement of Changes in Beneficial Ownership (4)

FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* CELGENE CORP /DE/	2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 86 MORRIS AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 11/3/2017
(Street) SUMMIT, NJ 07901 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/3/2017		S		22759	D	$19.10 ⁽¹⁾	4812221	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/6/2017		S		79327	D	$18.89 ⁽¹⁾	4732894	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/7/2017		S		23000	D	$18.54 ⁽¹⁾	4709894	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/8/2017		S		16875	D	$18.06 ⁽¹⁾	4693019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/9/2017		S		20000	D	$17.08 ⁽¹⁾	4673019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/10/2017		S		10000	D	$17.28 ⁽¹⁾	4663019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/13/2017		S		65093	D	$17.76 ⁽¹⁾	4597926	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/14/2017		S		14907	D	$17.19 ⁽¹⁾	4583019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/15/2017		S		15000	D	$17.67 ⁽¹⁾	4568019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/16/2017		S		105000	D	$18.39 ⁽⁴⁾	4463019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/17/2017		S		51282	D	$18.44 ⁽⁴⁾	4411737	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/20/2017		S		158718	D	$19.02 ⁽⁴⁾	4253019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/21/2018		S		80000	D	$19.25 ⁽⁴⁾	4173019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/22/2017		S		256000	D	$19.76 ⁽⁴⁾	3917019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/24/2017		S		26010	D	$20.00 ⁽⁴⁾	3891009	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/27/2017		S		27990	D	$19.75 ⁽⁴⁾	3863019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/28/2017		S		5080	D	$19.22 ⁽⁴⁾	3857939	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/29/2017		S		4263	D	$19.25 ⁽⁴⁾	3853676	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	11/30/2017		S		12666	D	$19.04 ⁽⁴⁾	3841010	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	12/1/2017		S		87991	D	$19.10 ⁽⁴⁾	3753019	I	See explanation of responses ⁽²⁾ ⁽³⁾
Common Stock	12/4/2017		S		30485	D	$19.47 ⁽⁴⁾	3722534	I	See explanation of responses ⁽²⁾ ⁽³⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4
(2)	These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.
(3)	Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CELGENE CORP /DE/ 86 MORRIS AVENUE SUMMIT, NJ 07901		X

Signatures
/s/ Peter N. Kellogg, Executive Vice President and Chief Financial Officer		12/6/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.